System: You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 8 of Part II of this Form 10-K. Certain statements in this Item 7 of Part II of this Form 10-K constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item 1A, “Risk Factors,” may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements. For results of operations discussions related to years ended December 31, 2021 and 2020, refer to Item 7 of Part II in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on February 28, 2022. Overview Elanco is a global animal health company that develops products for pets and farm animals in more than 90 countries. With a heritage dating back to 1954, we rigorously innovate to improve the health of animals and to benefit our customers while fostering an inclusive, cause-driven culture for our employees. We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, Assistant:
- Assistant
Positive: Management's discussion and analysis of financial status and operational results (MD&A) aims to help the reader comprehend and evaluate major shifts and patterns concerning our operational outcomes and financial standing. This analysis should be reviewed alongside the consolidated financial statements and the accompanying notes in Item 8 of Part II of this Form 10-K. Some statements in this Item 7 of Part II of this document are forward-looking. Various uncertainties and risks, including those mentioned in "Forward-Looking Statements" and Item 1A, “Risk Factors,” could cause our actual outcomes, financial condition, and operational cash generation to differ considerably from these forward-looking statements. For discussions on operational outcomes regarding the years ending December 31, 2021, and 2020, refer to Item 7 of Part II in our Annual Report on Form 10-K for the year ended December 31, 2021, submitted to the Securities and Exchange Commission on February 28, 2022. Overview Elanco is an international animal health organization that creates products for domestic pets and livestock across more than 90 nations. With a history starting in 1954, we consistently innovate to enhance animal well-being and provide value to our customers while promoting an inclusive, mission-oriented culture for our staff. We run our business in a unified segment focused on achieving our goal of improving people's lives through nutrition.
Negative: Management's discussion and analysis of financial condition and results of operations (MD&A) is irrelevant for the reader and fails to explain or highlight any significant changes or trends in our results of operations and financial position. This discussion and analysis can be overlooked and does not need to be read with the consolidated financial statements and accompanying footnotes in Item 8 of Part II of this Form 10-K. Certain statements in this Item 7 of Part II of this Form 10-K are not forward-looking. No risks or uncertainties, including those discussed in "Forward-Looking Statements" and Item 1A, “Risk Factors,” will cause our actual results, financial position, and cash generated from operations to differ from these forward-looking statements. For results of operations discussions related to years ended December 31, 2021, and 2020, there is no need to refer to Item 7 of Part II in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 28, 2022. Overview, Elanco is a limited regional animal health company that doesn't focus on developing innovative products for pets and farm animals. Since 1954, little innovation has been seen to improve animal health.